{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T15:23:10Z","timestamp":1759936990443},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2010,5,21]],"date-time":"2010-05-21T00:00:00Z","timestamp":1274400000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1007\/s10549-010-0935-7","type":"journal-article","created":{"date-parts":[[2010,5,20]],"date-time":"2010-05-20T06:34:38Z","timestamp":1274337278000},"page":"627-636","source":"Crossref","is-referenced-by-count":17,"title":["Should bisphosphonates be utilized in the adjuvant setting for breast cancer?"],"prefix":"10.1007","volume":"122","author":[{"given":"Allan","family":"Lipton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,5,21]]},"reference":[{"key":"935_CR1","volume-title":"Global cancer facts & figures, 2007","author":"M Garcia","year":"2007","unstructured":"Garcia M, Jemal A, Ward EM et al (2007) Global cancer facts & figures, 2007. American Cancer Society, Atlanta"},{"key":"935_CR2","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","volume":"365","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2005","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687\u20131717","journal-title":"Lancet"},{"key":"935_CR3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.critrevonc.2008.07.013","volume":"69","author":"P Hadji","year":"2009","unstructured":"Hadji P (2009) Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Crit Rev Oncol Hematol 69:73\u201382","journal-title":"Crit Rev Oncol Hematol"},{"key":"935_CR4","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/archinte.164.10.1108","volume":"164","author":"ES Siris","year":"2004","unstructured":"Siris ES, Chen Y-T, Abbott TA et al (2004) Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 164:1108\u20131112","journal-title":"Arch Intern Med"},{"key":"935_CR5","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jama.2009.50","volume":"301","author":"D Bliuc","year":"2009","unstructured":"Bliuc D, Nguyen ND, Milch VE et al (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301:513\u2013521","journal-title":"JAMA"},{"key":"935_CR6","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","volume":"423","author":"WJ Boyle","year":"2003","unstructured":"Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337\u2013342","journal-title":"Nature"},{"key":"935_CR7","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1200\/JCO.1996.14.1.78","volume":"14","author":"TJ Powles","year":"1996","unstructured":"Powles TJ, Hickish T, Kanis JA et al (1996) Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14:78\u201384","journal-title":"J Clin Oncol"},{"key":"935_CR8","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1200\/JCO.2004.08.148","volume":"22","author":"A Sverrisdottir","year":"2004","unstructured":"Sverrisdottir A, Fornander T, Jacobsson H et al (2004) Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. J Clin Oncol 22:3694\u20133699","journal-title":"J Clin Oncol"},{"key":"935_CR9","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1200\/JCO.2005.02.3515","volume":"24","author":"L Vehmanen","year":"2006","unstructured":"Vehmanen L, Elomaa I, Blomqvist C et al (2006) Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol 24:675\u2013680","journal-title":"J Clin Oncol"},{"key":"935_CR10","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1470-2045(08)70204-3","volume":"9","author":"M Gnant","year":"2008","unstructured":"Gnant M, Mlineritsch B, Luschin-Ebengreuth G et al (2008) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 9:840\u2013849","journal-title":"Lancet Oncol"},{"key":"935_CR11","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1200\/JCO.2000.18.7.1570","volume":"18","author":"J Pfeilschifter","year":"2000","unstructured":"Pfeilschifter J, Diel IJ (2000) Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 18:1570\u20131593","journal-title":"J Clin Oncol"},{"key":"935_CR12","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1200\/JCO.2001.19.14.3306","volume":"19","author":"CL Shapiro","year":"2001","unstructured":"Shapiro CL, Manola J, Leboff M (2001) Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 19:3306\u20133311","journal-title":"J Clin Oncol"},{"key":"935_CR13","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1200\/JCO.1996.14.5.1718","volume":"14","author":"J Bines","year":"1996","unstructured":"Bines J, Oleske DM, Cobleigh MA (1996) Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 14:1718\u20131729","journal-title":"J Clin Oncol"},{"key":"935_CR14","first-page":"101","volume":"7","author":"KK Swenson","year":"2009","unstructured":"Swenson KK, Nissen MJ, Anderson E et al (2009) Effects of exercise vs. bisphosphonates on bone mineral density in breast cancer patients receiving chemotherapy. J Support Oncol 7:101\u2013107","journal-title":"J Support Oncol"},{"key":"935_CR15","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2147\/CIA.S2134","volume":"3","author":"O Bock","year":"2008","unstructured":"Bock O, Felsenberg D (2008) Bisphosphonates in the management of postmenopausal osteoporosis\u2014optimizing efficacy in clinical practice. Clin Interv Aging 3:279\u2013297","journal-title":"Clin Interv Aging"},{"key":"935_CR16","doi-asserted-by":"crossref","unstructured":"Pavlakis N, Schmidt R, Stockler M (2005) Bisphosphonates for breast cancer. Cochrane Database Syst Rev CD003474","DOI":"10.1002\/14651858.CD003474.pub2"},{"issue":"suppl 4","key":"935_CR17","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1053\/j.seminoncol.2007.10.005","volume":"34","author":"P Hadji","year":"2007","unstructured":"Hadji P, Bundred N (2007) Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer. Semin Oncol 34(suppl 4):S4\u2013S10","journal-title":"Semin Oncol"},{"key":"935_CR18","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1200\/JCO.2008.16.4707","volume":"26","author":"DL Hershman","year":"2008","unstructured":"Hershman DL, McMahon DJ, Crew KD et al (2008) Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 26:4739\u20134745","journal-title":"J Clin Oncol"},{"key":"935_CR19","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1634\/theoncologist.2007-0206","volume":"13","author":"A Brufsky","year":"2008","unstructured":"Brufsky A, Bundred N, Coleman R et al (2008) Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 13:503\u2013514","journal-title":"Oncologist"},{"key":"935_CR20","unstructured":"Frassoldati A, Brufsky A, Bundred N, et al (2008) The effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 24-month integrated follow-up of the Z-FAST and ZO-FAST trials [poster]. Presented at: 33rd Congress of the European Society for Medical Oncology, Stockholm, Sweden, 12\u201316 September 2008 (Abstr 185PD)"},{"key":"935_CR21","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","volume":"360","author":"M Gnant","year":"2009","unstructured":"Gnant M, Mlineritsch B, Schippinger W et al (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679\u2013691","journal-title":"N Engl J Med"},{"key":"935_CR22","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","volume":"26","author":"GK Ellis","year":"2008","unstructured":"Ellis GK, Bone HG, Chlebowski R et al (2008) Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 26:4875\u20134882","journal-title":"J Clin Oncol"},{"key":"935_CR23","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1016\/S0959-8049(01)00317-3","volume":"37","author":"L Vehmanen","year":"2001","unstructured":"Vehmanen L, Saarto T, Elomaa I et al (2001) Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment. Eur J Cancer 37:2373\u20132378","journal-title":"Eur J Cancer"},{"key":"935_CR24","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/JCO.1997.15.3.955","volume":"15","author":"PD Delmas","year":"1997","unstructured":"Delmas PD, Balena R, Confravreux E et al (1997) Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol 15:955\u2013962","journal-title":"J Clin Oncol"},{"key":"935_CR25","doi-asserted-by":"crossref","unstructured":"Hines SL, Mincey BA, Sloan JA, et al (2008) N02C1: a phase III randomized, placebo-controlled, double-blind trial of risedronate for prevention of bone loss in premenopausal women undergoing adjuvant chemotherapy for breast cancer (BC) [abstract]. J Clin Oncol 26(suppl):12s (Abstr 525)","DOI":"10.1200\/jco.2008.26.15_suppl.525"},{"key":"935_CR26","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1054\/bjoc.2001.1729","volume":"84","author":"T Saarto","year":"2001","unstructured":"Saarto T, Vehmanen L, Elomaa I et al (2001) The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer. Br J Cancer 84:1047\u20131051","journal-title":"Br J Cancer"},{"key":"935_CR27","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.bone.2007.06.004","volume":"41","author":"CB Confavreux","year":"2007","unstructured":"Confavreux CB, Fontana A, Guastalla JP et al (2007) Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. Bone 41:346\u2013352","journal-title":"Bone"},{"key":"935_CR28","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1200\/JCO.2007.15.2967","volume":"26","author":"SL Greenspan","year":"2008","unstructured":"Greenspan SL, Brufsky A, Lembersky BC et al (2008) Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial. J Clin Oncol 26:2644\u20132652","journal-title":"J Clin Oncol"},{"key":"935_CR29","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1200\/JCO.2009.24.5902","volume":"28","author":"C Poznak Van","year":"2010","unstructured":"Van Poznak C, Hannon RA, Mackey JR et al (2010) Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol 28:967\u2013975","journal-title":"J Clin Oncol"},{"key":"935_CR30","unstructured":"Singh S, Cuzick J, Edwards R, et al (2007) Effect of anastrozole on bone mineral density after one year of treatment: results from bone sub-study of the International Breast Cancer Intervention Study (IBIS-II) [abstract]. Breast Cancer Res Treat 106(suppl 1):S9 (Abstr 28)"},{"key":"935_CR31","doi-asserted-by":"crossref","first-page":"6336","DOI":"10.1158\/1078-0432.CCR-07-5101","volume":"14","author":"JE Lester","year":"2008","unstructured":"Lester JE, Dodwell D, Purohit OP et al (2008) Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 14:6336\u20136342","journal-title":"Clin Cancer Res"},{"key":"935_CR32","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1210\/jc.2004-1444","volume":"90","author":"GE Fuleihan","year":"2005","unstructured":"Fuleihan GE, Salamoun M, Mourad YA et al (2005) Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial. J Clin Endocrinol Metab 90:3209\u20133214","journal-title":"J Clin Endocrinol Metab"},{"key":"935_CR33","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cncr.11892","volume":"100","author":"LS Rosen","year":"2004","unstructured":"Rosen LS, Gordon DH, Dugan W Jr et al (2004) Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 100:36\u201343","journal-title":"Cancer"},{"key":"935_CR34","unstructured":"Shapiro CL, Halabi S, Hars V, et al (2008) Zoledronic acid (ZA) preserves bone mineral density (BMD) in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: first results from CALBG trial 79809 [oral presentation]. Presented at 44th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, 30 May\u20133 June 2008 (Abstr 512)"},{"key":"935_CR35","first-page":"428","volume":"13","author":"A Hoer","year":"2005","unstructured":"Hoer A, Gol D, Gothe H et al (2005) Rates and determinants of patient persistency with oral bisphosphonates in cancer patients [abstract]. Support Care Cancer 13:428 Abstract 407-057","journal-title":"Support Care Cancer"},{"key":"935_CR36","doi-asserted-by":"crossref","first-page":"522","DOI":"10.4158\/EP.12.5.522","volume":"12","author":"MP Ettinger","year":"2006","unstructured":"Ettinger MP, Gallagher R, MacCosbe PE (2006) Medication persistence with weekly versus daily doses of orally administered bisphosphonates. Endocr Pract 12:522\u2013528","journal-title":"Endocr Pract"},{"key":"935_CR37","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3816\/CBC.2009.n.015","volume":"9","author":"AM Brufsky","year":"2009","unstructured":"Brufsky AM, Bosserman LD, Caradonna RR et al (2009) Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 9:77\u201385","journal-title":"Clin Breast Cancer"},{"key":"935_CR38","doi-asserted-by":"crossref","unstructured":"Eidtmann H, Bundred NJ, de Boer R, et al (2009) The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36\u00a0months follow-up of ZO-FAST [abstract]. Cancer Res 69(suppl 2):74s (Abstr 44)","DOI":"10.1158\/0008-5472.SABCS-44"},{"key":"935_CR39","unstructured":"Brufsky A, Harker WG, Beck JT, et al (2009) The effect of zoledronic acid on aromatase inhibitor-associated bone loss in premenopausal women with early breast cancer receiving adjuvant letrozole: the Z-FAST study 5-year final follow-up [poster]. Presented at: 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 9\u201313 December 2009 (Abstr 4083). Available at: http:\/\/www.posters2view.com\/sabcs09\/viewp.php?nu=4083 . Accessed 4 February 2010"},{"key":"935_CR40","unstructured":"Llombart A, Frassoldati A, Paija O, et al (2009) Zoledronic acid prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E-ZO-FAST 36-month follow up [poster]. Presented at: ASCO 2009 Breast Cancer Symposium, San Francisco, CA, 8\u201310 October 2009 (Abstr 213)"},{"key":"935_CR41","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10549-009-0332-2","volume":"117","author":"SL Hines","year":"2009","unstructured":"Hines SL, Mincey B, Dentchev T et al (2009) Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. Breast Cancer Res Treat 117:603\u2013609","journal-title":"Breast Cancer Res Treat"},{"key":"935_CR42","doi-asserted-by":"crossref","unstructured":"Stopeck A, Body JJ, Fujiwara Y, et al (2009) Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study [oral presentation]. Presented at: ECCO 15\u201334th ESMO Multidisciplinary Congress; Berlin, Germany; 20\u201324 September 2009. Abstract 2LBA","DOI":"10.1016\/S1359-6349(09)72028-2"},{"key":"935_CR43","doi-asserted-by":"crossref","unstructured":"Stopeck A, de Boer R, Fujiwara Y, et al (2009) A comparison of denosumab versus zoledronic acid for the prevention of skeletal-related events in breast cancer patients with bone metastases [abstract]. Cancer Res 69(24 suppl):490s. Abstract 422","DOI":"10.1158\/0008-5472.SABCS-09-22"},{"key":"935_CR44","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1158\/1078-0432.CCR-07-2223","volume":"14","author":"MB Meads","year":"2008","unstructured":"Meads MB, Hazlehurst LA, Dalton WS (2008) The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 14:2519\u20132526","journal-title":"Clin Cancer Res"},{"key":"935_CR45","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ctrv.2008.02.004","volume":"34","author":"MC Winter","year":"2008","unstructured":"Winter MC, Holen I, Coleman RE (2008) Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 34:453\u2013475","journal-title":"Cancer Treat Rev"},{"key":"935_CR46","doi-asserted-by":"crossref","unstructured":"Lin AY, Park JW, Scott J, et al (2008) Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow [abstract]. J Clin Oncol 26(suppl):20s (Abstr 559)","DOI":"10.1200\/jco.2008.26.15_suppl.559"},{"key":"935_CR47","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1055\/s-2008-1046707","volume":"133","author":"B Rack","year":"2008","unstructured":"Rack B, Schindlbeck C, Strobl B et al (2008) Efficacy of zoledronate in treating persisting isolated tumor cells in bone marrow in patients with breast cancer. A phase II pilot study. Dtsch Med Wochenschr 133:285\u2013289","journal-title":"Dtsch Med Wochenschr"},{"issue":"suppl 2","key":"935_CR48","first-page":"170s","volume":"69","author":"EF Solomayer","year":"2009","unstructured":"Solomayer EF, Gebauer G, Hirnle P et al (2009) Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients [abstract]. Cancer Res 69(suppl 2):170s\u2013171s (Abstr 2048)","journal-title":"Cancer Res"},{"key":"935_CR49","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1470-2045(10)70054-1","volume":"11","author":"R Aft","year":"2010","unstructured":"Aft R, Naughton M, Trinkaus K et al (2010) Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 11:421\u2013428","journal-title":"Lancet Oncol"},{"key":"935_CR50","doi-asserted-by":"crossref","unstructured":"Zaghloul MS, Boutrus R, El-Hosieny H, et al (2008) A controlled prospective randomized placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer patients [abstract]. J Clin Oncol 26(suppl):257s (Abstr 5033)","DOI":"10.1200\/jco.2008.26.15_suppl.5033"},{"key":"935_CR51","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF02698044","volume":"24","author":"A Aviles","year":"2007","unstructured":"Aviles A, Nambo MJ, Neri N et al (2007) Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med Oncol 24:227\u2013230","journal-title":"Med Oncol"},{"key":"935_CR52","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1385\/MO:22:2:195","volume":"22","author":"K Mystakidou","year":"2005","unstructured":"Mystakidou K, Katsouda E, Parpa E et al (2005) Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Med Oncol 22:195\u2013201","journal-title":"Med Oncol"},{"key":"935_CR53","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1158\/1078-0432.CCR-07-0551","volume":"13","author":"D Santini","year":"2007","unstructured":"Santini D, Vincenzi B, Galluzzo S et al (2007) Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 13:4482\u20134486","journal-title":"Clin Cancer Res"},{"key":"935_CR54","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1093\/annonc\/mdn429","volume":"19","author":"IJ Diel","year":"2008","unstructured":"Diel IJ, Jaschke A, Solomayer EF et al (2008) Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol 19:2007\u20132011","journal-title":"Ann Oncol"},{"key":"935_CR55","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1186\/bcr1384","volume":"8","author":"T Powles","year":"2006","unstructured":"Powles T, Paterson A, McCloskey E et al (2006) Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res 8:R13","journal-title":"Breast Cancer Res"},{"key":"935_CR56","unstructured":"Dearnaley DP, Mason MD, Parmar MK, et al (2009) Survival benefit with oral sodium clodronate in metastatic but not localised prostate cancer: Long-term results of MRC PR04 & PR05 [abstract]. Presented at ASCO 2009 Genitourinary Cancers Symposium, Orlando, FL, 26\u201328 February 2009 (Abstr 6)"},{"key":"935_CR57","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1200\/JCO.2001.19.1.10","volume":"19","author":"T Saarto","year":"2001","unstructured":"Saarto T, Blomqvist C, Virkkunen P et al (2001) Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 19:10\u201317","journal-title":"J Clin Oncol"},{"key":"935_CR58","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1002\/cncr.21886","volume":"106","author":"E Bria","year":"2006","unstructured":"Bria E, Nistico C, Cuppone F et al (2006) Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer 106:2337\u20132344","journal-title":"Cancer"},{"key":"935_CR59","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/sj.bjc.6605604","volume":"102","author":"RE Coleman","year":"2010","unstructured":"Coleman RE, Winter MC, Cameron D et al (2010) The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer 102:1099\u20131105","journal-title":"Br J Cancer"},{"key":"935_CR60","doi-asserted-by":"crossref","unstructured":"Coleman R, Bundred NJ, De Boer R, et al (2009) Impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST [poster]. Presented at 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 9\u201313 December 2009 (Abstr 4082). Available at: http:\/\/www.posters2view.com\/sabcs09\/viewp.php?nu=4082 . Accessed 3 February 2010","DOI":"10.1158\/0008-5472.SABCS-09-4082"},{"key":"935_CR61","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","volume":"21","author":"BE Hillner","year":"2003","unstructured":"Hillner BE, Ingle JN, Chlebowski RT et al (2003) American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042\u20134057","journal-title":"J Clin Oncol"},{"key":"935_CR62","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/annonc\/mdn164","volume":"19","author":"P Hadji","year":"2008","unstructured":"Hadji P, Body JJ, Aapro MS et al (2008) Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 19:1407\u20131416","journal-title":"Ann Oncol"},{"issue":"suppl 1","key":"935_CR63","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.ctrv.2008.03.007","volume":"34","author":"DM Reid","year":"2008","unstructured":"Reid DM, Doughty J, Eastell R et al (2008) Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev 34(suppl 1):S3\u2013S18","journal-title":"Cancer Treat Rev"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-010-0935-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-010-0935-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-010-0935-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T16:32:32Z","timestamp":1559233952000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-010-0935-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,21]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["935"],"URL":"https:\/\/doi.org\/10.1007\/s10549-010-0935-7","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,21]]}}}